Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ

Cancer Immunology Immunotherapy

Volumn 49, Issue 1, 2000, Pages 34-45

  Pulaski, Beth A ^a   Clements, Virginia K ^a   Pipeling, Matthew R ^a   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

Angiogenesis; CD4+ T cells; CD80; IL 12; Immunotherapy; Metastatic mammary carcinoma; MHC class II

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOKINE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; IMMUNOSTIMULATION; LYMPHOCYTE DEPLETION; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

EID: 0033946489     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050024     Document Type: Article

References (45)

1. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90: 5687
2. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181: 619
3. Brunda M (1994) Interleukin-12. J Leukoc Biol 55: 280
4. Brunda M, Luistro L, Warrier L, Wright R, Hubbard B, Murphy M, Wolf S, Gately M (1993) Anti-tumor and anti-metastatic activity of IL-12 against murine tumors. J Exp Med 178: 1223
5. Cavallo F, Di Carlo E, Butera M, Verrua R, Colombo M, Musiani P, Forni G (1999) Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 59: 414
6. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093
7. Chen L, Chen D, Block E, O'Donnell M, Kufe D, Clinton S (1997) Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 159: 351
8. Chen P, Geer D, Podack E, Ksander B (1996) Tumor cells transfected with B7-1 and interleukin-12 cDNA induce protective immunity. Ann NY Acad Sci 795: 325
9. Chong H, Todryk S, Hutchinson G, Hart I, Vile R (1998) Tumor cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther 5: 223
10. Colombo M, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, Stoppacciaro G (1996) Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res 56: 2531
11. Coughlin C, Wysocka M, Kurzawa H, Lee W, Trinchieri G, Eck S (1995) B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 55: 4980
12. Coughlin C, Salhany K, Gee M, LaTemple C, Kotenko S, Ma X, Gri G, Wysocka M, Kim J, Liu L, Liao F, Farber J, Pestka S, Trinchieri G, Lee W (1998) Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9: 25
13. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M (1997) Requirement for V alpha 14 NKT cells in il-12-mediated rejection of tumors. Science 278: 1623
14. Fallarino F, Ashikari A, Boon T, Gajewski T (1997) Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12 but not B7-1 transfected tumor cells. Int Immunol 9: 1259
15. Farber J (1997) Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61: 246
16. Fidler J, Hart I (1982) Biological diversity in metastatic neoplasms: Origins and implications. Science 217: 998
17. Gajewski T, Renauld J, Van Pel A, Boon T (1995) Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of marine antitumor cytolytic T lymphocytes in vitro. J Immunol 154: 5637
18. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547
19. Janeway C, Conrad P, Lerner E, Babich J, Wettstein P, Murphy D (1984) Monoclonal antibodies specific for Ia glycoproteins raised by immunization with activated T cells: Possible role of t cell-bound Ia antigens as targets of immunoregulatory T cells. J Immunol 132: 662
20. Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber J, Liao L, Tosato G (1998) Contribution of the CXC chemokines IP-10 and mig to the antitumor effects of IL-12. J Leukoc Biol 64: 384
21. Kappler J, Skidmore B, White J, Marrack P (1981) Antigen-inducible, H-2-restricted, IL-2 producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J Exp Med 153: 1198
22. Kato K, Okumura K, Yagita H (1997) Immunoregulation by B7 and IL-12 gene transfer. Leukemia 11 [Suppl 3]: 572
23. Kubin M, Kamoun M, Trinchieri G (1994) Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 180: 211
24. Miller F, Miller B, Heppner G (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: Heterogeneity in phenotypic stability. Invasion Metastasis 3: 22
25. Murphy E, Terres G, Macatonia E, Hsieh C, Mattson J, Lanier L, Wysocka M, Trinchieri G, Murphy K, O'Garra A (1994) B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 180: 223
26. b antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma. J Immunol 141: 4403
27. Ostrand-Rosenberg S (1994) Tumor immunotherapy: The tumor cell as an antigen-presenting cell. Curr Opin Immunol 6: 722
28. Ostrand-Rosenberg S, Thakur A, Clements V (1990) Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 144: 4068
29. Ostrand-Rosenberg S, Baskar S, Patterson N, Clements V (1996) Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47: 414
30. Ozato K, Sachs D (1981) Monoclonal antibodies to mouse MHC antigens. J Immunol 126: 317
31. Pizzoferrato E, Chu N, Hawley T, Lieu F, Barber B, Hawley R, Watts T, Berinstein N (1997) Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12. Hum Gene Ther 8: 2217
32. Pulaski B, Ostrand-Rosenberg S (1998) MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth. Cancer Res 58: 1486
33. Putzer B, Hitt M, Muller W, Emtage P, Gauldie J, Graham F (1997) Interluekin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 94: 10 889
34. Rao J, Chamberlain R, Bronte V, Carroll M, Irvine K, Moss B, Rosenberg S, Restifo N (1996) IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression. J Immunol 156: 3357
35. Sarmiento M, Glasebrook A, Fitch F (1980) IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell mediated cytolysis in the absence of complement. J Immunol 125: 2665
36. Sgadari C, Angiolillo A, Tosato G (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87: 3877
37. Sgadari C, Farber J, Angiolillo A, Liao F, Teruya-Feldstein J, Burd P, Yao L, Gupta G, Kanegane C, Tosato G (1997) Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89: 2635
38. Tahara H, Zeh H, Storkus W, Pappo I, Watkins C, Gubler U, Wolf S, Robbins P, Lotze M (1994) Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54: 182
39. Tahara H, Zitvogel L, Storkus W, Zeh H, McKinney T, Schreiber R, Gubler U, Robbins PD, and Lotze M (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154: 6466
40. Tannenbaum C, Tubbs R, Armstrong D, Finke J, Bukowski R, Hamilton T (1998) The CXC chemokines IP-10 and mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161: 927
41. + T cells by B7-transfected melanoma cells. Science 259: 368
42. Wilde D, Marrack P, Kappler J, Dialynis D, Fitch F (1983) Evidence implicating L3T4 in class II MHC antigen reactivity: Monoclonal antibody GK1.5 blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol 131: 2178
43. Yao L, Sgadari C, Furuke K, Bloom E, Teruya-Feldstein J, Tosato G (1999) Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93: 1612
44. Zar J (1984) Multisample hypotheses: The analysis of variance. In: Biostatistical Analysis. Prentice-Hall, Englewood, NJ, p 162
45. Zitvogel L, Robbins P, Storkus W, Clarke M, Maeurer M, Campbell R, Davis C, Tahara H, Schreiber R, Lotze M (1996) Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 26: 1335